Seventure Partners
Seventure Partners is a Paris-based venture capital firm founded in 1997, specializing in investments in life sciences and information and communication technology. With offices in Munich, Geneva, London, and Basel, the firm manages approximately €660 million and focuses on identifying and nurturing innovative companies with high growth potential across North America, Europe, Asia-Pacific, the Middle East, and Africa. Seventure Partners engages closely with entrepreneurs, leveraging its expertise and extensive networks to support the development of emerging European leaders in their respective fields. The firm employs a team of over 20 professionals, including 15 investors, who possess significant knowledge in technology and private equity operations. Seventure’s investment strategy encompasses various sectors, including TMT, industrial, healthcare devices, and supply, with a typical investment range of €0.5 million to €2 million over a six-year horizon.
MaaT Pharma, SA, operates as a biotechnology company. It develops therapies to treat diseases related to gut microbiota imbalance. It also develops a series of microbiome-based drugs which targets mortality and comorbidities associated with blood cancer treatment. The company was founded in 2014 and is based in Lyon, France.
LiMM Therapeutics operates as a biopharmaceutical company that harnesses the molecular cross-talk between neuronal and innate lymphoid cells. It develops products designed to preserve health and treat inflammatory, infectious, and metabolic diseases. The company is dedicated to bridging neural sensing and immunology discoveries to unlock therapeutic solutions for the benefit of patients.
LiMM Therapeutics operates as a biopharmaceutical company that harnesses the molecular cross-talk between neuronal and innate lymphoid cells. It develops products designed to preserve health and treat inflammatory, infectious, and metabolic diseases. The company is dedicated to bridging neural sensing and immunology discoveries to unlock therapeutic solutions for the benefit of patients.
MaaT Pharma, SA, operates as a biotechnology company. It develops therapies to treat diseases related to gut microbiota imbalance. It also develops a series of microbiome-based drugs which targets mortality and comorbidities associated with blood cancer treatment. The company was founded in 2014 and is based in Lyon, France.
MaaT Pharma, SA, operates as a biotechnology company. It develops therapies to treat diseases related to gut microbiota imbalance. It also develops a series of microbiome-based drugs which targets mortality and comorbidities associated with blood cancer treatment. The company was founded in 2014 and is based in Lyon, France.
MaaT Pharma, SA, operates as a biotechnology company. It develops therapies to treat diseases related to gut microbiota imbalance. It also develops a series of microbiome-based drugs which targets mortality and comorbidities associated with blood cancer treatment. The company was founded in 2014 and is based in Lyon, France.
TME Pharma is a biotechnology company based in Berlin, Germany, focused on developing innovative therapeutics for cancer treatment. The company utilizes its proprietary Spiegelmer platform, which involves biostable aptamers and mirror image nucleic acids, to create a pipeline of clinical-stage product candidates. Its lead drug candidate, NOX-A12, is being investigated as a combination therapy for various cancer types, including metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia. TME Pharma is also advancing NOX-E36, which has completed Phase IIa trials for diabetic nephropathy. The company has established partnerships, including a collaboration with Merck & Co. to explore the efficacy of NOX-A12 in combination with Keytruda in patients with metastatic solid tumors. Founded in 1997, TME Pharma continues to advance its mission of developing novel treatments for serious medical conditions.